Excerpt from Ophthalmology Advisor.
Using in vitro and in vivo models of glaucoma, cannabinoids (CBs) demonstrated neuroprotection, stopped changes in extracellular matrix (ECM), and normalized intraocular pressure (IOP) levels in the eye, showing a possible therapeutic intervention for the irreversible eye disease, according to a study published in BBA Molecular Basis of Disease.
Since glaucoma is notable for progression in retinal ganglion cells (RGCs), a therapy is needed to stop that damage: Enter CBs, researchers say. Prior research has shown that CBs potentially lower IOP, helping stop RGC degeneration and optic nerve (ON) damage; however, the direct correlation of specific CBs with molecular events in glaucoma pathology has not been well established. Hence this study, which looked to better determine cannabinol’s (CBN) role in these factors with CBN and other CBs sourced from several locations used in the mouse 661W retinal ganglion precursor-like cell line and primary human TM (hTM) cells isolated from the juxtacanalicular and corneoscleral regions of the human eye.
